Varian’s Robust Results – Analyst Blog
Zacks Market Commentaries (October 30th, 2009) Writes:
Zacks Market Commentaries (October 30th, 2009) Writes:
Zacks Market Commentaries (October 14th, 2009) Writes:
The Pharma division of SAFC, a member of the leading Life Science and High Technology company, Sigma-Aldrich Group (SIAL) has completed the expansion of its Carlsbad, California facility. The facility conducts contract-manufacturing services for SAFC’s late phase and commercial clients. The $12 million expansion project included the addition of two fully segregated viral product-manufacturing suites built to employ the latest in disposable bioreactor technologies. This is aimed to expand SAFC Pharma's biologics, viral vaccines and gene therapy manufacturing to commercial quantities.
SAFC Pharma's Carlsbad site specializes in the process development and manufacturing of viral vaccines and viral therapeutics − including a full menu of support services − from preclinical process and analytical development to final fill/finish and commercial bulk drug supplies. The new expansion, designed for multi-lot campaigns, includes dedicated cell expansion, bioreactor production, purification and cleanroom suites. The expansion will enable both 100-liter batch production in stirred tank bioreactors
...
Contrarian Profits (September 14th, 2009) Writes:
It’s official: You can reduce your investment risk simply by chucking darts at a list of stocks, then buying them.
That’s if you believe a Nobel economist, of course. His crude “experiment” was the start of “modern portfolio theory” decades ago. The downside, however, was that with a reduction of risk came a dampening of profits. So scratch that idea.
How about this? A startling study in the late 1970s showed that owning a portfolio of large U.S. companies with international divisions drops your risk 10% below a domestic stock portfolio. Much better. But that wasn’t the eye-popper…
The study also found that owning stocks in international companies cuts your risk in half…
Take that, “efficiency” theorists! Yet the stuffy professors still tried to refute these results. It was a losing battle, though, as more studies emerged, laden with more evidence that international stocks reduce risk.
But the
...
Michael Vlaicu (September 13th, 2009) Writes:
Imaging3, Inc.
(Public, OTC:IMGG)
A new and radical medical device from Imaging3 Inc. (OTC:IMGG) is ready to set the standard, and revolutionize the way we look at X-ray, MRI and CT scans. Imaging 3 is currently awaiting FDA approval on their DViS (Dominion Volumetric Imaging Scanner). Currently, medical imaging is met with challenges of long waits, lack of space, lack of mobility, and limited uses. However, for the first time ever, health-care workers will be able to instantly view 3D, high-resolution images of virtually any part of the human body. Thus, Imaging 3 looks to change all that. Saving time, saving lives and reducing costs. This technology will “set the standard for the next 10 years.” The following article was composed by StocksHaven Investments alongside Professor Philip Runfeldt, a Behavioral Analyst who has worked with Fortune 500 companies and major Universities throughout
...
Zacks Market Commentaries (August 26th, 2009) Writes:
Volcano's s5i is a component-based system that is incorporated directly into the catheterization lab, commonly known as the cath lab, thereby allowing intravascular ultrasound (IVUS) and fractional flow reserve (FFR) systems to remain always ON and ready. The company's IVUS and FFR systems are compatible with Siemens' Artis x-ray offerings.
The new agreement appears to be a win-win for both companies. Volcano's top-line will be substantially benefited by the agreement with the global giant. On the other hand, Siemens is a technology leader in the cath lab market focusing on a complete cath lab package. Siemens should benefit from the agreement as Volcano's s5i IVUS and FFR systems are
...
Penny Omega (August 5th, 2009) Writes:
PennyOmega.com Stock Report!
PennyOmega.com Hot Stock News & Alerts!
Wednesday August 5, 2009
PennyOmega.com Stock Report!
**************************************************************
American Science and Engineering, Inc. (NASDAQ: ASEI), a leading worldwide supplier of innovative X-ray detection solutions, announced today the introduction of the Sentry(TM) Portal — a high-throughput, high-penetration, drive-through cargo inspection system designed to quickly and safely scan trucks, cargo containers, and tanker trucks for threatening materials, weapons, and contraband. The Sentry Portal system is safe for drivers and operators and offers the unique combination of high-penetration capability with unsurpassed image quality. The system is an ideal solution for high-volume seaports, border crossings, and security checkpoints. The Sentry Portal system can also be deployed along with AS&E’s multi-view Z Portal(R) screening
...
Dr. Stock Pick (July 21st, 2009) Writes:
DrStockPick.com Stock Report!
Tuesday, July 21, 2009
**************************************************************
Sport Supply Group (NASDAQ:RBI) today stated that preliminary results for its fiscal year ended June 30, 2009 - subject to the completion of its year end audit - indicate annual sales of more than $250 Million and diluted earnings per share of $0.84 - $0.87 cents versus diluted earnings per share of $0.76 in the prior fiscal year. This represents the highest level of income produced in the Company’s 37 year history.
Critical backup power systems manufacturer Active Power, Inc. (NASDAQ: ACPW) today announced it has received and shipped an order for a CleanSource(R) 1200 kVA UPS (uninterruptible power supply) system to Naples Daily News, the major daily newspaper for Collier County, Fla. The flywheel-based UPS system will
...
QualityStocks (July 7th, 2009) Writes:
Access Pharmaceuticals, Inc. announced earlier this morning new preclinical data demonstrating that thiarabine, one of the company’s advanced drug delivery technologies, shows extraordinary efficacy in preventing and treating rheumatoid arthritis (RA). In a well-established animal model for RA, a remarkable restoration of joint structure was observed. The studies were conducted at Wayne State University School of Medicine and at Southern Research Institute.
According to the press release, thiarabine treatment resulted in a broad inhibition of disease pathology, with reduction of both inflammatory and erosive disease parameters, as well as protection from loss of cartilage matrix proteins. When used as a preventative treatment, thiarabine blocked the development of joint disease at the 60 mg/kg/day dose level and exhibited a considerable reduction in disease incidence and severity at 20 mg/kg/day.
Perhaps even more exciting, in a therapeutic study comparing thiarabine to methotrexate, a commonly used clinical drug for RA treatment, high resolution
...
Contrarian Profits (June 2nd, 2009) Writes:
Green Mountain Coffee Roasters produced a return of over 113% this year alone. When powerful momentum stocks are charging upwards, it can be difficult to know when to get on board. But it’s not as difficult as you would believe.
If you want the inside track on the best momentum stocks with ultra-explosive gains, throw on your “x-ray glasses” and focus on one of the most useful financial ratios around.
It’s called return on equity (ROE), but in many ways it tells us so much more.
ROE is one of the best measures of a corporation’s profitability. It shows you how much profit the company generates with the money shareholders have invested. Let me show you how to easily pull this number out - and how profitable it can be.
How to Calculate Return On Equity (ROE)
You calculate return on equity (ROE) by dividing net income by a shareholder’s equity. The higher the
...
Investment U (June 1st, 2009) Writes:
Return On Equity (ROE): Find Explosive Momentum Stocks With This Financial Ratio
by Dr. Scott Brown, Education Director, Investment U
Green Mountain Coffee Roasters produced a return of over 113% this year alone. When powerful momentum stocks are charging upwards, it can be difficult to know when to get on board.
But it’s not as difficult as you would believe.
If you want the inside track on the best momentum stocks with ultra-explosive gains, throw on your “x-ray glasses” and focus on one of the most useful financial ratios around.
It’s called return on equity (ROE), but in many ways it tells us so much more.
ROE is one of the best measures of a corporation’s profitability. It shows you how much profit the company generates with the money shareholders have invested. Let me show you how to easily pull this number out - and how profitable it can be.
How to Calculate
...